Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11826053 | 0.82 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL2575098 | 0.79 | LMNA (0.46) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL7711095 | 0.79 | LMNA (0.46) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL385724 | 0.76 | LMNA (0.55) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL1179123 | 0.76 | LMNA (0.55) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL4896893 | 0.76 | LMNA (0.55) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL5808127 | 0.76 | LMNA (0.55) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL5088000 | 0.76 | LMNA (0.48) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL28644100 | 0.74 | LMNA (0.52) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL31173902 | 0.73 | LMNA (0.40) | LMNAKMT2AMEN1THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | CHATTOPADHYAYA JYOTI (SE) | 2004-07-22 | — | — | US | claimed |
| EP-1332150-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | Chattopadhyaya, Jyoti (SE) | 2003-08-06 | — | — | EP | claimed |
| WO-2002038578-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | CHATTOPADHYAYA JYOTI (SE) | 2002-05-16 | — | — | WO | claimed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| US-5430139-A | Viricides; effective against herpes and cytomegalo viruses | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1995-07-04 | — | — | US | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| US-5300636-A | 2'-alkylidenepyrimidine nucleoside compounds and a process for production of same | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1994-04-05 | — | — | US | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
| US-5189027-A | Hypotensive agent, vasoconstriction | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1993-02-23 | — | — | US | claimed |
| US-5068340-A | Antagonist of platelet activating factor for treatment of asthma, inflammation or shock | SANKYO COMPANY, LIMITED (JP) | 1991-11-26 | — | — | US | claimed |
| US-20240238321-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | SYNTHENA AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-4396354-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-10 | — | — | EP | disclosed |
| EP-0260121-A2 | Inosose derivatives, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-03-16 | — | — | EP | disclosed |
| EP-0240175-A1 | Inosose derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-10-07 | — | — | EP | disclosed |
| EP-0238202-A2 | Glycerol derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1987-09-23 | — | — | EP | disclosed |
| EP-0200522-A2 | Process for preparing griseolic acid derivatives | SANKYO COMPANY LIMITED (JP) | 1986-11-05 | — | — | EP | disclosed |
| US-4297502-A | Aromatic bisazomethines, a method for their preparation, and their use as reactive pigments | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) | 1981-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | RNASEH1, RNASEL, NSUN2 | LMNA 384/4885KMT2A 1336/4885MEN1 4771/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | LMNA 1868/4885KMT2A 2211/4885MEN1 2026/4885 |
| US-20240238321-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | MTPN, UTRN, DCTD | LMNA 46/4885KMT2A 2603/4885MEN1 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.